Acetyldigitoxin
Acetyldigitoxin may decrease the cardiotoxic activities of Nivolumab.
Ancestim
The risk or severity of cytotoxicity can be increased when Ancestim is combined with Nivolumab.
Anthrax immune globulin, human
The therapeutic efficacy of Anthrax immune globulin human can be decreased when used in combination with Nivolumab.
Advertisement
BCG Vaccine
The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Nivolumab.
BCG, Live, Connaught Strain
The therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Nivolumab.
BCG, Live, Tice Strain
The therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Nivolumab.
Advertisement
Belimumab
The risk or severity of adverse effects can be increased when Nivolumab is combined with Belimumab.
Bevacizumab
Bevacizumab may increase the cardiotoxic activities of Nivolumab.
Bevacizumab-Awwb
Bevacizumab may increase the cardiotoxic activities of Nivolumab.
Advertisement
Cabazitaxel
The risk or severity of adverse effects can be increased when Cabazitaxel is combined with Nivolumab.
Cyclophosphamide
Cyclophosphamide may increase the cardiotoxic activities of Nivolumab.
Cyclophosphamide Anhydrous
Cyclophosphamide may increase the cardiotoxic activities of Nivolumab.
Deslanoside
Deslanoside may decrease the cardiotoxic activities of Nivolumab.
Digitoxin
Digitoxin may decrease the cardiotoxic activities of Nivolumab.
Digoxin
Digoxin may decrease the cardiotoxic activities of Nivolumab.
Docetaxel
The risk or severity of adverse effects can be increased when Docetaxel is combined with Nivolumab.
DOCETAXEL ANHYDROUS
The risk or severity of adverse effects can be increased when Docetaxel is combined with Nivolumab.
Hepatitis A Vaccine, Inactivated
The therapeutic efficacy of Hepatitis A Vaccine can be decreased when used in combination with Nivolumab.
Hepatitis B Surface Antigen Vaccine
The therapeutic efficacy of Hepatitis B Vaccine (Recombinant) can be decreased when used in combination with Nivolumab.
Ouabain
Ouabain may decrease the cardiotoxic activities of Nivolumab.
Ovine Digoxin Immune Fab
Digoxin Immune Fab (Ovine) may decrease the cardiotoxic activities of Nivolumab.
Paclitaxel
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Nivolumab.
Proscillaridin
Proscillaridin may decrease the cardiotoxic activities of Nivolumab.
Rabies Immune Globulin, Human
The therapeutic efficacy of Human rabies virus immune globulin can be decreased when used in combination with Nivolumab.
Rabies Virus Vaccine Flury-Lep Strain
The therapeutic efficacy of Rabies virus inactivated antigen, A can be decreased when used in combination with Nivolumab.
ROTAVIRUS VACCINE, LIVE
The therapeutic efficacy of Rotavirus Vaccine can be decreased when used in combination with Nivolumab.
Rubella Virus Vaccine Live (wistar Ra 27-3 Strain)
The therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Nivolumab.
Salmonella enterica subsp. enterica serovar typhi
The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Nivolumab.
Tetanus Toxoid Vaccine, Inactivated
The therapeutic efficacy of Clostridium tetani toxoid antigen (formaldehyde inactivated) can be decreased when used in combination with Nivolumab.
Trastuzumab
Trastuzumab may increase the cardiotoxic activities of Nivolumab.
Typhoid Vaccine Live Ty21a
The therapeutic efficacy of Salmonella typhi ty21a live antigen can be decreased when used in combination with Nivolumab.
Typhoid Vi Polysaccharide Vaccine, S typhi Ty2 strain
The therapeutic efficacy of Salmonella typhi ty2 vi polysaccharide antigen can be decreased when used in combination with Nivolumab.
Varicella Virus Vaccine Live (Oka-Merck) strain
The therapeutic efficacy of Varicella Zoster Vaccine (Live/Attenuated) can be decreased when used in combination with Nivolumab.
Yellow Fever Vaccine
The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Nivolumab.
Yellow-Fever Virus Vaccine, 17D-204 strain
The therapeutic efficacy of Yellow Fever Vaccine can be decreased when used in combination with Nivolumab.
